Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
At the moment there is a lack of data in the setting of oligometastatic PC in particular
regarding the interaction between ablative SBRT, ADT and patient's immune system response.
The hypothesis underlying this project consists in the idea that the patient's immunological
context, RT and ADT may interact in the context of metastatic PC. Indeed the immune landscape
of patients may interfere with the efficacy of SBRT and on the other side RT may modulate the
immune response by driving immunotolerance.
Scope of the study will be to investigate the immune modulation after SBRT in:
- patients with diagnosis of oligorecurrence during a treatment-free interval
- patients with oligoprogression or oligopersistance during hormonal therapy